Skip to main content
SpringerLink
Log in

Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment- case study and review of literature

  • Letter to the Editor
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Temozolomide is an alkylating agent used frequently in the management of gliomas. Although temozolomide is generally safe, rarely it can cause life threatening complications. Here we report the cases of two patients who developed prolonged and severe pancytopenia after low dose continuous temozolomide concurrently with cranial radiotherapy. The pancytopenia lasted two to six months. Both the patients were young, treatment naïve, and had temozolomide treatment for only approximately four weeks.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Stupp R, Mason WP, van den Bent MJ et al (2005) radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

    Article  PubMed  CAS  Google Scholar 

  2. Spence AM, Kiem HP, Partap S, Schuetze S, Silber JR, Peterson RA (2006) Complications of a temozolomide overdose: a case report. J Neuro-Oncol 80:57–61

    Article  Google Scholar 

  3. Hartmann P, Herholz K, Salzberger B, Petereit HF (2004) Unusual and severe symptomatic impairment of neutrophil function after one cycle of temozolomide in patients with malignant gliomas. Ann Hematol 83:212–217

    Article  PubMed  CAS  Google Scholar 

  4. Su YW, Chang MC, Chiang MF, Hsieh RK (2005) Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. J Neuro-Oncol 71(3):315–318

    Article  Google Scholar 

  5. Noronha V, Berliner N, Ballen KK, Lacy J, Kracher J, Baehring J, Henson JW (2006) Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature. Neuro-oncol 8(3):280–283

    Article  PubMed  Google Scholar 

  6. Doyle TJ, Mikkelsen T, Croteau D et al (2005) Fatal hematologic toxicity with prolonged continuous administration of temozolomide (TMZ) during radiation therapy (RT) in the treatment of newly-diagnosed glioblastoma multiforme (GBM): Report of a Phase II trial. J Clin Oncol, ASCO Annual Meeting Proceedings 23 (16S):1546

    Google Scholar 

  7. Villano JL, Collins CA, Manasanch EE et al (2006) Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide. Lancet Oncol 7:436–438

    Article  PubMed  Google Scholar 

  8. Fink D, Aebi S, Howell SB (1998) The role of DNA mismatch repair in drug resistance. Clin Cancer Res 4:1–6

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, SA, 5000, Australia

    Nimit Singhal, Sudarshan Selva-Nayagam & Michael P Brown

Authors
  1. Nimit Singhal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sudarshan Selva-Nayagam
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael P Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nimit Singhal.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Singhal, N., Selva-Nayagam, S. & Brown, M.P. Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment- case study and review of literature. J Neurooncol 85, 229–230 (2007). https://doi.org/10.1007/s11060-007-9403-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-007-9403-6

Keywords

Search

Navigation